Today I'm sitting down with Randy Teel, Ph.D., President and CEO of Arvinas, a clinical-stage biotech based in New Haven, Connecticut, that is doing something genuinely new in medicine.
Arvinas is pioneering a technology called PROTAC protein degradation. It's a platform that doesn't just block disease-causing proteins, but eliminates them entirely using the body's own disposal system to do it. It's a fundamental shift in how we think about drug design, and it's now reached a historic milestone: the first PROTAC ever to succeed in a Phase 3 clinical trial, with a regulatory filing now in front of the FDA.
01:19 Meet Randy Teel
03:41 Stepping into the CEO role in February 2026
13:17 What is a PROTAC and how it works
17:37 Vepdegestrant and the first PROTAC approval
23:43 Balancing partnerships versus keeping control of assets
31:57 Key milestones to watch in the next 12–18 months
Podden och tillhörande omslagsbild på den här sidan tillhör
Labiotech. Innehållet i podden är skapat av Labiotech och inte av,
eller tillsammans med, Poddtoppen.
